ID

22315

Description

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Investigational Product Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast

Lien

https://clinicaltrials.gov/ct2/show/NCT00078572

Mots-clés

Versions (1)
  1. 29/05/2017 29/05/2017 -
Téléchargé le

29 mai 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Investigational Product NCT00078572

Anglais

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Investigational Product NCT00078572

1 Formulaires  
Investigational Product - GW572016
Description

Investigational Product - GW572016

Alias
UMLS CUI-1
C0304229
Dose
Description

Dose

Type de données

float

Unités de mesure
  • mg
Alias
UMLS CUI [1,1]
C3174092
UMLS CUI [1,2]
C0304229
mg
Start date
Description

Start date

Type de données

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C0304229
Stop date
Description

Stop date

Type de données

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C0304229
If there were any dosing deviations / changes, give reason(s)
Description

reason for dosing deviations changes

Type de données

integer

Alias
UMLS CUI [1,1]
C1515926
UMLS CUI [1,2]
C0304229
UMLS CUI [1,3]
C0392360
Investigational Product Compliance
Description

Investigational Product Compliance

Alias
UMLS CUI-1
C0304229
UMLS CUI-2
C1321605
Date tablets dispensed
Description

Date tablets dispensed

Type de données

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C1514756
UMLS CUI [1,3]
C0304229
Number of tablets dispensed
Description

Number of tablets dispensed

Type de données

integer

Alias
UMLS CUI [1,1]
C0805077
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C0304229
Number of tablets returned
Description

Number of tablets returned

Type de données

integer

Alias
UMLS CUI [1,1]
C2699071
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C0304229
Investigational Product - Capecitabine
Description

Investigational Product - Capecitabine

Alias
UMLS CUI-1
C0671970
Dose
Description

Dose

Type de données

float

Unités de mesure
  • mg
Alias
UMLS CUI [1,1]
C3174092
UMLS CUI [1,2]
C0304229
mg
Start date
Description

Start date

Type de données

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C0304229
Stop date
Description

Stop date

Type de données

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C0304229
If there were any dosing deviations / changes, give reason(s)
Description

reason for dosing deviations changes

Type de données

integer

Alias
UMLS CUI [1,1]
C1515926
UMLS CUI [1,2]
C0304229
UMLS CUI [1,3]
C0392360
Date tablets dispensed
Description

Date tablets dispensed

Type de données

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C1514756
UMLS CUI [1,3]
C0671970
Tablet Strength in mg
Description

Tablet Strength in mg

Type de données

integer

Unités de mesure
  • mg
Alias
UMLS CUI [1]
C0671970
mg
Number of tablets dispensed
Description

Number of tablets dispensed

Type de données

integer

Alias
UMLS CUI [1,1]
C0805077
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C0671970
Number of tablets returned
Description

Number of tablets returned

Type de données

integer

Alias
UMLS CUI [1,1]
C2699071
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C0671970
Investigational Product Discontinuation
Description

Investigational Product Discontinuation

Alias
UMLS CUI-1
C0304229
UMLS CUI-2
C0457454
Was the investigational product stopped permanently?
Description

investigational product stopped

Type de données

text

Alias
UMLS CUI [1,1]
C0304229
UMLS CUI [1,2]
C0457454
If YES, check the primary reason the investigational product was stopped permanently, check one:
Description

primary reason the investigational product was stopped

Type de données

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0304229
UMLS CUI [1,3]
C0457454
primary reason the investigational product was stopped: If other, please specify
Description

primary reason the investigational product was stopped

Type de données

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0304229
UMLS CUI [1,3]
C0457454
Retour au début de la page

Similar models

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Investigational Product NCT00078572

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Investigational Product - GW572016
C0304229 (UMLS CUI-1)
Dose
Item
Dose
float
C3174092 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Start date
Item
Start date
date
C0808070 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Stop date
Item
Stop date
date
C0806020 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Item
If there were any dosing deviations / changes, give reason(s)
integer
C1515926 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,3])
reason for dosing deviations changes
Code List
If there were any dosing deviations / changes, give reason(s)
CL Item
Hematological toxicity (31)
CL Item
Non-Hematological toxicity (6)
CL Item
Subject non-compliant (9)
CL Item
Other (99)
Item Group
Investigational Product Compliance
C0304229 (UMLS CUI-1)
C1321605 (UMLS CUI-2)
Date tablets dispensed
Item
Date tablets dispensed
date
C0011008 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
Number of tablets dispensed
Item
Number of tablets dispensed
integer
C0805077 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
Number of tablets returned
Item
Number of tablets returned
integer
C2699071 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
Item Group
Investigational Product - Capecitabine
C0671970 (UMLS CUI-1)
Dose
Item
Dose
float
C3174092 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Start date
Item
Start date
date
C0808070 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Stop date
Item
Stop date
date
C0806020 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Item
If there were any dosing deviations / changes, give reason(s)
integer
C1515926 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
C0392360 (UMLS CUI [1,3])
reason for dosing deviations changes
Code List
If there were any dosing deviations / changes, give reason(s)
CL Item
Hematological toxicity (31)
CL Item
Non-Hematological toxicity (6)
CL Item
Subject non-compliant (9)
CL Item
Other (99)
Date tablets dispensed
Item
Date tablets dispensed
date
C0011008 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C0671970 (UMLS CUI [1,3])
Tablet Strength in mg
Item
Tablet Strength in mg
integer
C0671970 (UMLS CUI [1])
Number of tablets dispensed
Item
Number of tablets dispensed
integer
C0805077 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0671970 (UMLS CUI [1,3])
Number of tablets returned
Item
Number of tablets returned
integer
C2699071 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C0671970 (UMLS CUI [1,3])
Item Group
Investigational Product Discontinuation
C0304229 (UMLS CUI-1)
C0457454 (UMLS CUI-2)
Item
Was the investigational product stopped permanently?
text
C0304229 (UMLS CUI [1,1])
C0457454 (UMLS CUI [1,2])
investigational product stopped
Code List
Was the investigational product stopped permanently?
CL Item
Yes (Y)
CL Item
No (N)
Item
If YES, check the primary reason the investigational product was stopped permanently, check one:
text
C0392360 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
C0457454 (UMLS CUI [1,3])
primary reason the investigational product was stopped
Code List
If YES, check the primary reason the investigational product was stopped permanently, check one:
CL Item
Adverse event (A)
CL Item
Consent withdrawn (C)
CL Item
Lost to follow up (L)
CL Item
Protocol violation (P)
CL Item
Progression of cancer (PD)
CL Item
Death (D)
CL Item
Discontinuation of study by sponsor (B)
CL Item
Other (X)
primary reason the investigational product was stopped
Item
primary reason the investigational product was stopped: If other, please specify
text
C0392360 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
C0457454 (UMLS CUI [1,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial